Urigen Pharmaceuticals, Inc. and Hyaluron Contract Manufacturing, Inc. Enter into Drug Development Agreement for URG101
Partnership Will Focus On Developing Product To Target Painful Bladder Syndrome
BURLINGAME, Calif.--(BUSINESS WIRE)--Urigen Pharmaceuticals, Inc. (OTCBB: URGP,
http://www.urigen.com), a specialty pharmaceutical company focused on the development and commercialization of treatments for urological disorders, and Hyaluron Contract Manufacturing, Inc. (
www.hyaluron.com), a leading provider of aseptic manufacturing services to companies in the pharmaceutical and biotechnology industries, have established a partnership to develop URG101, Urigen’s proprietary fixed dose combination of FDA-approved drugs targeting painful bladder syndrome (PBS).
“Urigen’s development program with Hyaluron is a critical step forward for URG101,” commented William J. Garner, MD, President and CEO of Urigen. “Hyaluron, with its quality-focused and innovative drug development team, makes an excellent partner for us as URG101 progresses through its development. We look forward to working with the drug development team at Hyaluron to provide a solution to PBS through the commercialization of our product.”
“We are very pleased to have been selected by Urigen to undertake the development of their kit targeting PBS,” stated Shawn Kinney, President of HCM. “The collaborative spirit already demonstrated by both companies’ employees bodes well for a successful development program.”
About Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen’s two lead programs target significant unmet medical needs and major market opportunities in urology. Urigen’s URG101 project targets painful bladder syndrome/interstitial cystitis, which affects approximately 10.5 million men and women in North America. Urigen’s URG301 project targets urethritis and acute urgency in patients diagnosed with an overactive bladder, a major unmet need that is insufficiently managed by presently available overactive bladder drugs. URG301 is a proprietary dosage form of an approved drug that is locally delivered to control urinary urgency. For further information, please visit Urigen’s website at
http://www.urigen.com.
About Hyaluron Contract Manufacturing
Hyaluron Contract Manufacturing (HCM) is a leader in aseptic contract manufacturing of filled liquid parenterals and medical devices. Since 1999, HCM has been offering its customers—from newly established firms to large-scale commercial enterprises—innovative and unique solutions to all their aseptic formulation/fill needs. At the core of HCM’s business is a commitment to quality, regulatory compliance and on-time delivery. HCM is located in Burlington MA. For further information, visit
www.hyaluron.com.
URGP...Urigen Pharmaceuticals Inc. (OTC BB)
Linear Mode
